PHARNEXT: Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on. | May 25, 2023
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on
PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
PARIS, France, January 11th, 2023, 8:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for rare